Previous 10 | Next 10 |
Atossa Therapeutics (ATOS): FY GAAP EPS of -$1.97 misses by $0.76.Cash, cash equivalents and restricted cash of $39.7M.Press Release For further details see: Atossa Therapeutics EPS misses by $0.76
SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announced financ...
Physician-Scientist Steven Quay Provides Open Letter Response to WHO Report: Five Undisputed Facts Support the Laboratory Origin of the COVID Virus PR Newswire SEATTLE , March 30, 2021 /PRNewswire/ -- An Open Letter concerning the WHO Report was published today b...
Gainers: Seneca Biopharma (SNCA) +25%, DarioHealth (DRIO) +25%, Dyadic International DYAI +24%, Marker Therapeutics (MRKR) +19%, Immunocore Holdings (IMCR) +11%.Losers: Odonate Therapeutics ODT -76%, Foghorn Therapeutics (FHTX) -13%,...
Atossa Therapeutics (ATOS) has priced a $50M direct offering at $2.88, a combined purchase price that include one common share and .75 warrant to purchase one common share.The company plans has to sell 17,361,100 shares of the common stock and issue unregistered warrants to purchase up to an ...
SEATTLE, March 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncolog...
Atossa Therapeutics (ATOS) announces the FDA has issued a "Safe to Proceed" letter under their Expanded Access Pathway, permitting the use of the company's oral Endoxifen as a treatment in an ovarian cancer patient.If the drug combination shows promise in the patient, Atossa will consider doi...
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases today announced the FDA has is...
MediciNova (MNOV) +87% on BARDA partnership for Ibudilast development.Cemtrex (CETX) +85%.Koss Corporation (KOSS) +50%.Obalon Therapeutics (OBLN) +34%.Enveric Biosciences (ENVB) +39% on agreement to acquire exclusive license for novel molecules from Diverse Biotech.MoneyGram Interna...
Penny Stocks to Watch As Markets Try To Recover With major blue-chip stocks pushing up by big numbers on Tuesday, which penny stocks are investors watching? Now this question comes with multiple parts as it truly depends on a few factors. Overall, we have to consider the current state o...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...